Merck to sell some ophthalmology assets for at least $600M


Merck (MRK) has agreed to sell some ophthalmology products to Santen Pharmaceutical (SNPHY) for $600M upfront plus milestone payments.

The deal covers Japan, as well as "key markets" in Europe and Asia Pacific, with the products generating $400M in annual sales in those regions.

The transaction follows Merck's sale of its U.S. ophthalmology business to Akorn Pharmaceuticals.

Merck will continue to sell ophthalmology products in various markets, including Latin America, Canada, Australia, and EMEA. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs